50 results on '"Wang, Yucai"'
Search Results
2. Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T.
3. Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).
4. Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori?
5. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
6. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
7. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course
8. Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.
9. Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.
10. Outcomes in mantle cell lymphoma with central nervous system involvement.
11. Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).
12. Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.
13. Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.
14. Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.
15. Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
16. Insurance status and survival in diffuse large B-cell lymphoma: A National Cancer Database study before and after the Affordable Care Act.
17. Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.
18. Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.
19. Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?
20. Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucel: Does age matter?
21. The impact of body weight and body mass index on outcomes of diffuse large B-cell lymphoma treated with axicabtagene ciloleucel.
22. Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index (CLL-IPI).
23. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
24. Influence of radiation therapy on the outcome of T1-2N0M0 triple-negative breast cancer: A SEER population-based retrospective analysis.
25. Pooled subgroup analysis of twelve randomized controlled trials of immunotherapy in non-small cell lung cancer.
26. Association of sex, age and ECOG performance status with cancer immunotherapy efficacy in randomized controlled trials.
27. Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials.
28. Association of SOX9 expression with sensitivity to CDK7 inhibition and overall survival in triple-negative breast cancer.
29. Outcomes of stem cell transplant in patients with Richter transformation.
30. Clinical predictors of efficacy for immune checkpoint inhibition in lung cancer patients.
31. Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.
32. Distinct immune signatures in chronic lymphocytic leukemia (CLL) and Richter’s syndrome (RS).
33. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
34. Representation of minorities in oncology clinical trials: Review of the past 14 years.
35. Impact of metformin use in the outcomes of multiple myeloma patients post stem cell transplant.
36. A comparison of liver cancer and lung cancer patients at two Veteran Affairs Medical Centers.
37. Comorbidities limiting recruitment of colorectal cancer (CRC) patients in early-phase trials.
38. Palliative care interventions and end-of-life care outcomes for hepatocellular patients (pts) at two Veterans Affairs (VA) medical centers.
39. A comparison of patients with liver cancer receiving palliative care at two Veterans Affairs (VA) Medical Centers.
40. A measure of intratumor heterogeneity to predict metastasis and metastasis-free survival in patients with triple-negative breast cancer.
41. Docetaxel in the treatment of metastatic hormone-sensitive and castration-resistant prostate cancer: A meta-analysis.
42. A comparison of liver cancer patients receiving palliative care at two Veteran Affairs Medical Centers.
43. A single institution retrospective review of characteristics and outcomes of patients requiring chronic dose reduction of TKIs given as front-line therapy for chronic phase CML.
44. Post-gastrectomy complications and mortality in elderly patients with gastric cancer: A population-based study.
45. Palliative care interventions and EOL care outcomes for hepatocellular patients (pts) at 2 VA medical centers.
46. Prognostic role of androgen receptor expression in triple-negative breast cancer.
47. Lenalidome in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial.
48. Rituximab maintenance Therapy in B-cell lymphoma: A meta-analysis.
49. Adding VEGFR-TKIs to chemotherapy and/or hormonal therapy in advanced breast cancer patients: Results of a meta-analysis.
50. Incidence and risk of diarrhea in cancer patients treated with pertuzumab: Evidence from published studies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.